Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
Empatica
Empatica Inc. is an MIT Media Lab spinoff company born in Cambridge, Massachusetts, operating in Healthcare, providing AI-enabled tools to advance forecasting, monitoring, research, and treatment. Empatica produces medical-grade wearables, software and algorithms for the collection and interpretation of physiological data. Empatica's wearables, Embrace2 and E4, track physiological signals such as Heart Rate Variability, electrodermal activity, acceleration and movement, skin temperature, and autonomic arousal. Embrace2 has been cleared by the FDA as a seizure alerting solution for epilepsy patients with generalized tonic-clonic seizures. The E4 is used by researchers for real-time physiological data capture. The company is headquartered in Boston, MA with offices in Milan, Italy, and Seoul, South Korea.[citation needed]
Empatica Inc. was founded in 2013 in Cambridge, Massachusetts, by Matteo Lai, Simone Tognetti, Maurizio Garbarino and Rosalind Picard. Picard serves as part-time chief scientist and chairman of the board, while Lai is full-time CEO, Tognetti is CTO, and Garbarino is CSA.
In 2014, in partnership with The Epilepsy Foundation, Empatica launched a crowdfunding campaign on Indiegogo for the creation of a wrist-worn device for monitoring and alerting to grand mal seizures, and help reduce cases of Sudden Unexpected Death in Epilepsy (SUDEP). This device was called Embrace.
In January 2018 Embrace (both the hardware and its Alert software) received FDA-clearance for adults and became the first medical wristwatch to be cleared by FDA for use in Epilepsy. In November 2018 an updated version of the Embrace, called Embrace2, was released.
In January 2019, Embrace2 received FDA-clearance for children ages 6 and up.
In November 2022, the Empatica Health Monitoring Platform received FDA-clearance for continuous data collection to monitor SpO2, electrodermal activity, skin temperature, and activity associated with movement during sleep.
The NASA-funded Translational Research Institute for Space Health (TRISH) is working with Empatica to develop a smartwatch able to monitor the health of the astronauts that will be on board the first crewed mission to Mars.
Since 2018, Empatica has been working in partnership with the U.S. Government's BARDA Division of Research, Innovation and Ventures (DRIVe), under the Department of Health and Human Services (HHS), to collaborate on the development of a new smartwatch which will alert users when they are developing a serious respiratory infection before any symptoms appear.
Hub AI
Empatica AI simulator
(@Empatica_simulator)
Empatica
Empatica Inc. is an MIT Media Lab spinoff company born in Cambridge, Massachusetts, operating in Healthcare, providing AI-enabled tools to advance forecasting, monitoring, research, and treatment. Empatica produces medical-grade wearables, software and algorithms for the collection and interpretation of physiological data. Empatica's wearables, Embrace2 and E4, track physiological signals such as Heart Rate Variability, electrodermal activity, acceleration and movement, skin temperature, and autonomic arousal. Embrace2 has been cleared by the FDA as a seizure alerting solution for epilepsy patients with generalized tonic-clonic seizures. The E4 is used by researchers for real-time physiological data capture. The company is headquartered in Boston, MA with offices in Milan, Italy, and Seoul, South Korea.[citation needed]
Empatica Inc. was founded in 2013 in Cambridge, Massachusetts, by Matteo Lai, Simone Tognetti, Maurizio Garbarino and Rosalind Picard. Picard serves as part-time chief scientist and chairman of the board, while Lai is full-time CEO, Tognetti is CTO, and Garbarino is CSA.
In 2014, in partnership with The Epilepsy Foundation, Empatica launched a crowdfunding campaign on Indiegogo for the creation of a wrist-worn device for monitoring and alerting to grand mal seizures, and help reduce cases of Sudden Unexpected Death in Epilepsy (SUDEP). This device was called Embrace.
In January 2018 Embrace (both the hardware and its Alert software) received FDA-clearance for adults and became the first medical wristwatch to be cleared by FDA for use in Epilepsy. In November 2018 an updated version of the Embrace, called Embrace2, was released.
In January 2019, Embrace2 received FDA-clearance for children ages 6 and up.
In November 2022, the Empatica Health Monitoring Platform received FDA-clearance for continuous data collection to monitor SpO2, electrodermal activity, skin temperature, and activity associated with movement during sleep.
The NASA-funded Translational Research Institute for Space Health (TRISH) is working with Empatica to develop a smartwatch able to monitor the health of the astronauts that will be on board the first crewed mission to Mars.
Since 2018, Empatica has been working in partnership with the U.S. Government's BARDA Division of Research, Innovation and Ventures (DRIVe), under the Department of Health and Human Services (HHS), to collaborate on the development of a new smartwatch which will alert users when they are developing a serious respiratory infection before any symptoms appear.